Navigation Links
Antibiotic resistance spreads rapidly between bacteria
Date:4/11/2011

The part of bacterial DNA that often carries antibiotic resistance is a master at moving between different types of bacteria and adapting to widely differing bacterial species, shows a study made by a research team at the University of Gothenburg in cooperation with Chalmers University of Technology. The results are published in an article in the scientific journal Nature Communications.

More and more bacteria are becoming resistant to our common antibiotics, and to make matters worse, more and more are becoming resistant to all known antibiotics. The problem is known as multi-resistance, and is generally described as one of the most significant future threats to public health Antibiotic resistance can arise in bacteria in our environment and in our bodies. Antibiotic resistance can then be transferred to the bacteria that cause human diseases, even if the bacteria are not related to each other.

A large proportion of gene transfer between bacteria takes place with the aid of what are known as conjugative plasmids, a part of the bacterial DNA. A plasmid can only exist and multiply inside a cell, where it uses the cell's machinery, but can then be transferred to another cell and in that way spread between bacteria.

The research team has studied a group of the known carriers of antibiotic resistance genes: IncP-1 plasmids. Using advanced DNA analysis, the researchers have succeeded in mapping the origin of different IncP-1 plasmids and their mobility between different bacterial species. "Our results show that plasmids from the IncP-1 group have existed in, and adapted to, widely differing bacteria. They have also recombined, which means that a single plasmid can be regarded as a composite jigsaw puzzle of genes, each of which has adapted to different bacterial species", says Peter Norberg, a researcher in the Institute of Biomedicine at the University of Gothenburg. This indicates very good adaptability and suggests that these plasmids can move relatively freely between, and thrive in, widely differing bacterial species.

"IncP-1 plasmids are very potent 'vehicles' for transporting antibiotic resistance genes between bacterial species. Therefore, it does not matter much in what environment, in what part of the world, or in what bacterial species antibiotic resistance arises. Resistance genes could relatively easily be transported from the original environment to bacteria that infect humans, through IncP-1 plasmids, or other plasmids with similar properties, as 'vehicles'," says Professor Malte Hermansson of the Department of Cell and Molecular Biology at the University of Gothenburg.

It has been known for some time that plasmids are important in the spread of antibiotic resistance. The research team's findings show that IncP-1 plasmids can move, and have moved, between widely differing bacterial species and in addition have interacted directly with one another, which can increase the potential for gene spreading.


'/>"/>

Contact: Peter Norberg
peter.norberg@gu.se
46-073-531-6166
University of Gothenburg
Source:Eurekalert  

Related medicine news :

1. Giant Eagle Pharmacy Free Antibiotics Program Surpasses $3 Million in Free Prescriptions
2. Poll: Hypothetical anthrax attack and antibiotics
3. Chitosan as alternative to growth-promoting antibiotics for ruminants
4. Penicillin Allergy Might Not Include Related Antibiotic
5. Hard to Treat Diseases (HTDS) Awarded Two Antibiotics Certificates For Chile
6. ID physicians call for 10 new antibiotics by 2020
7. Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study
8. Misinformation about antibiotics can travel to large audience via Twitter: study
9. Researchers find compound effective in destroying antibiotic-resistant biofilms
10. Antibiotic regimen effective for reactive arthritis
11. Combination antibiotics effective against chlamydia-induced arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Antibiotic resistance spreads rapidly between bacteria
(Date:8/22/2017)... ... 22, 2017 , ... “To Walk Away”: a captivating and romantic sequel ... Koontz. “To Walk Away” is the creation of published author, Larry R. Sherman, a ... manuscripts in chemistry and religion, as well as four novels. , Though the ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Covert Awakening”: Walid’s spiritual ... published author, Julianne Hale, a consultant for the Intelligence Community. For more ... on the Near East region. Julianne has written hundreds of reports for ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... TopConsumerReviews.com recently ... to fight Fatigue . , As the stress of modern life continually makes ... the pace. Constant use of artificial stimulants can trap people in vicious high/low cycles ...
(Date:8/21/2017)... ... , ... PracticeMatch, a company that provides online resources , job ... practitioners like nurse practitioners and physician assistants , will conduct its ... year. The online career fairs will allow job seekers to connect with healthcare employers ...
(Date:8/21/2017)... ... August 21, 2017 , ... Los ... plastic surgery fellows for academic year 2017-2018, Christina M. Busuito, M.D. and Lukasz ... completed residency in Plastic and Reconstructive Surgery. The candidate will have the ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... E.I. Medical Imaging (EIMI) has partnered with ... design the worlds first ultrasound system to be used underwater ... habitat. In preparation for a piece produced by Icon ... Dr. Guttridge approached EIMI with the idea of an underwater ... sharks underwater. EIMI ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
(Date:7/25/2017)... CAMBRIDGE, Massachusetts , July 25, 2017 The ... treat rare nervous system diseases, has concluded a worldwide license ... the drug SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing ... in a Phase 2 study conducted in Europe ... the United States ...
Breaking Medicine Technology: